Analysis of bone selective estrogen and androgen receptor modulators.
| Project/Area Number |
22790062
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | Tokyo University of Agriculture and Technology |
|---|
Principal Investigator |
HIRATA Michiko 東京農工大学, 大学院・工学研究院, 助教 (40544060)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Keywords | 骨粗鬆症 / エストロゲン / アンドロゲン / 受容体作働薬 |
|---|
| Research Abstract |
Bone remodeling is regulated by osteoclastic bone resorption and new bone formation. Estrogen deficiency induced by menopause results in marked bone loss in women. The elderly men exhibit marked bone loss due to androgen deficiency. We developed the new anti-osteoporosis drugs with minimal undesired effects on reproductive tissues. Carboranes restored bone loss in ovariectomized mice and orchidectomized mice without estrogenic activity or androgenic action in the sex organs. Therefore, Carboranes are novel selective estrogen receptor modulators(SERM) that may offer a new therapy option for osteoporosis.
|
Report
(3 results)
Research Products
(25 results)
